Glucotrack, Inc. Issues Joint Press Release with Lokahi Therapeutics

What Happened

• Glucotrack, Inc. (a Delaware corporation) filed a Form 8‑K on July 30, 2026 under Item 7.01 (Regulation FD Disclosure) to furnish a joint press release with Lokahi Therapeutics Inc. The press release is dated July 29, 2026 and is provided as Exhibit 99.1 to the filing.

Key Details

• Item reported: 7.01 — Regulation FD Disclosure (joint press release with Lokahi Therapeutics Inc.).
• Press release date: July 29, 2026; furnished as Exhibit 99.1 to the Form 8‑K.
• Filing date: Form 8‑K submitted July 30, 2026; Exhibit 104 (Cover Page Interactive Data File) is included.
• The press release information was furnished (Regulation FD) in the 8‑K (i.e., provided to the SEC and made public), rather than designated as “filed” with potential additional legal implications.

Why It Matters

• The Form 8‑K makes public a joint announcement between Glucotrack and Lokahi Therapeutics; investors should read Exhibit 99.1 (the press release) for the substantive details of the announcement. Because the information was furnished under Regulation FD, it was broadly disclosed to the market as of the press release date (July 29, 2026).